logo-loader
viewAstraZeneca

AstraZeneca granted Breakthrough Therapy Designation for rare genetic condition treatment

A breakthrough therapy designation is designed to expedite the development and review of medicines that are intended to treat a serious condition and have shown promise in early-stage clinical trials

laboratory
NF1 is a rare genetic condition that people are born with and can lead to learning difficulties

AstraZeneca PLC’s (LON:AZN) potential treatment for a rare genetic condition called neurofibromatosis type 1 (NF1) has been granted breakthrough therapy designation (BTD) by US regulators.

The move from the US Food and Drug Administration effectively fast-tracks the regulatory review of the medicine, called selumetinib, which Astra is working on with fellow pharma giant Merck & Co Inc (NYSE:MRK).

READ: AstraZeneca launches UK's biggest cash call this year

NF1 is a rare genetic condition that causes tumours to grow along a person’s nerves which can lead to various skin issues and learning difficulties, as well as problems with the bones, eyes and nervous system.

People with NF1 also have a much higher rate of cancer and cardiovascular disease.

The BTD is based on data from a Phase II monotherapy trial last summer which showed that selumetinib can reduce pain and motor impairment.

“Selumetinib shows promise in the treatment of NF1-related plexiform neurofibromas, a rare and debilitating disease with no approved medications to date,” said Astra’s oncology R&D boss José Baselga.

“The Breakthrough Therapy Designation acknowledges the significant unmet need of these patients and the potential benefit of selumetinib in this setting.”

Quick facts: AstraZeneca

Price: 8589 GBX

LSE:AZN
Market: LSE
Market Cap: £112.71 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Redx Pharma PLC's Lisa Anson updates on lead asset RXC004 and increased...

Redx Pharma PLC's (LON:REDX) Lisa Anson recaps on its lead product RXC004 which is in a Phase I clinical trial and is part of a potentially breakthrough group of cancer drugs called Porcupine inhibitors. Anson also details the recent investment by its majority shareholder Redmile which has...

1 hour, 24 minutes ago

2 min read